InvestorsHub Logo
Followers 59
Posts 7372
Boards Moderated 0
Alias Born 10/20/2014

Re: zumantu post# 270586

Thursday, 04/30/2020 8:32:01 PM

Thursday, April 30, 2020 8:32:01 PM

Post# of 424150
Zumantu, Obviously, none of us know what AMRN is doing with regard to
the potential that Vascepa may have for the inflammatory effects of the
C-19 virus. Sadly, it appears not very many on this board even care
to discuss it. Personally, this could be very significant but will be
laid to waste if not handled properly. With some luck maybe a BP
somewhere is doing their own studies to figure out how Valuable
Vascepa may be if they owned AMRN. If the virus causes residual
inflammatory damage this could make Vascepa valuable as a treatment
for anyone with elevated systemic inflammation after having had
the virus. I doubt JT has the gravitas to understand what this
could mean, perhaps some BP might. (If I could I would bring
this to the attention of the military command authorities to
find out if Vascepa would be beneficial if taken by every active
duty military member.)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News